Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group.

Bromley CM, Close S, Cohen N, Favis R, Fijal B, Gheyas F, Liu W, Lopez-Correa C, Prokop A, Singer JB, Snapir A, Tchelet A, Wang D, Goldstaub D; Industry Pharmacogenomics Working Group.

Pharmacogenomics J. 2009 Feb;9(1):14-22. doi: 10.1038/tpj.2008.11. Epub 2008 Sep 16. Review.

PMID:
18794908
2.

Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.

Bar-Zohar D, Agosta F, Goldstaub D, Filippi M.

Mult Scler. 2008 Jul;14(6):719-27. doi: 10.1177/1352458507088102. Epub 2008 Apr 18. Review.

PMID:
18424478
3.

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

Grossman I, Avidan N, Singer C, Goldstaub D, Hayardeny L, Eyal E, Ben-Asher E, Paperna T, Pe'er I, Lancet D, Beckmann JS, Miller A.

Pharmacogenet Genomics. 2007 Aug;17(8):657-66.

PMID:
17622942
4.

Putrescine activates oxidative stress dependent apoptotic death in ornithine decarboxylase overproducing mouse myeloma cells.

Erez O, Goldstaub D, Friedman J, Kahana C.

Exp Cell Res. 2002 Nov 15;281(1):148-56.

PMID:
12441138
5.

Poliovirus 2A protease induces apoptotic cell death.

Goldstaub D, Gradi A, Bercovitch Z, Grosmann Z, Nophar Y, Luria S, Sonenberg N, Kahana C.

Mol Cell Biol. 2000 Feb;20(4):1271-7.

6.
7.

Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors.

Soker S, Goldstaub D, Svahn CM, Vlodavsky I, Levi BZ, Neufeld G.

Biochem Biophys Res Commun. 1994 Sep 15;203(2):1339-47.

PMID:
7522446

Supplemental Content

Loading ...
Support Center